Meeting
2019 ASCO Annual Meeting
Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma.
Authors
Ping Zhou
Tufts Medical Center, Boston, MA
Ping Zhou , Adin Kugelmass , Denis Toskic , Amandeep Godara , Teresa Fogaren , Cindy Varga , Ray Comenzo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Plasma Cell Disorders
Clinical Trial Registration Number
NCT02741999
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8010)
DOI
10.1200/JCO.2019.37.15_suppl.8010
Abstract #
8010
Poster Bd #
336
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT).
First Author: Chakra Pani Chaulagain
Poster
2020 ASCO Virtual Scientific Program
Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.
First Author: Iuliana Vaxman
Poster
2020 ASCO Virtual Scientific Program
Genetic polymorphisms associated with clostridium difficile infection in multiple myeloma patients undergoing autologous stem cell transplantation.
First Author: Issam Hamadeh
Poster
2019 ASCO Annual Meeting
Outcomes of patients with t(11;14) multiple myeloma: An international myeloma working group (IMWG) multicenter study.
First Author: Brian G. Durie